Haleon Buys Back Shares for £12.25M
Ticker: HLNCF · Form: 6-K · Filed: Sep 16, 2024 · CIK: 1900304
Sentiment: neutral
Topics: share-buyback, treasury-shares
TL;DR
Haleon just bought back 1.5M shares for £12.25M on Sept 16. Treasury shares incoming.
AI Summary
Haleon plc announced on September 16, 2024, that it repurchased 1,500,000 of its ordinary shares at an average price of £8.1666 per share. The total cost of these repurchases amounted to approximately £12,249,900. These shares will be held as treasury shares.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of share repurchases and does not indicate any new or significant risks.
Key Numbers
- 1,500,000 — Shares Repurchased (Haleon plc bought back this many ordinary shares.)
- £12.25M — Total Cost (The aggregate amount spent on the share repurchase.)
Key Players & Entities
- Haleon plc (company) — Registrant
- 1,500,000 (dollar_amount) — Number of shares repurchased
- £8.1666 (dollar_amount) — Average price per share
- £12,249,900 (dollar_amount) — Total cost of repurchases
- September 16, 2024 (date) — Date of transaction
FAQ
What was the total number of Haleon plc shares repurchased on September 16, 2024?
Haleon plc repurchased 1,500,000 ordinary shares.
What was the average price paid per share for the repurchased shares?
The average price paid per share was £8.1666.
What is the total monetary value of the share repurchase transaction?
The total cost of the repurchases was approximately £12,249,900.
What will happen to the repurchased shares?
The repurchased shares will be held as treasury shares.
What is the filing date of this report?
This Form 6-K was filed on September 16, 2024.
Filing Stats: 543 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-09-16 12:41:24
Filing Documents
- a3696e.htm (6-K) — 29KB
- 0001654954-24-011930.txt ( ) — 30KB
From the Filing
IN OWN SHARES a3696e UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2024   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1  16 September 2024 - Transaction in Own Shares         99.1       Haleon plc:   Transaction in own shares   16 September 2024:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of the following number of ordinary shares of £0.01 each in the Company (the "Shares") for cancellation   under its share buyback programme announced on 1 August 2024   (the "Buyback Programme").   Date of purchase: 16 September 2024 Number of Shares purchased: 656,800 Highest price paid per Share (p): 397.3000 Lowest price paid per Share (p): 393.7000 Volume weighted average price paid per Share (p): 395.8035   Following the settlement of the above, the Company's registered share capital consists of 9,118,471,572 ordinary shares. This figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5s(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/3963E_1-2024-9-16.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Sonya Ghobrial   +44 7392 784784 Zo ë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Gemma Thomas +44 7985 175048 Emma White +44 7823 523562     Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .                SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 16, 2024 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary